Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 9
2004 5
2005 6
2006 4
2007 4
2008 9
2009 4
2010 4
2011 5
2012 4
2013 5
2014 12
2015 13
2016 10
2017 11
2018 20
2019 22
2020 19
2021 20
2022 24
2023 20
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells.
Ma L, Ramasubramanian R, Mehta NK, Cossette B, Morgan DM, Sukaj I, Bergaggio E, Kadauke S, Myers RM, Paruzzo L, Ghilardi G, Grzywa TM, Cozzone A, Schuster SJ, Frey N, Zhang L, Yousefpour P, Abraham W, Suh H, Ruella M, Grupp SA, Chiarle R, Wittrup KD, Irvine DJ. Ma L, et al. Among authors: schuster sj. bioRxiv [Preprint]. 2024 Apr 17:2024.04.16.589780. doi: 10.1101/2024.04.16.589780. bioRxiv. 2024. PMID: 38659938 Free PMC article. Preprint.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, Chong EA, Gabrielli G, Nasta SD, Landsburg DJ, Carter J, Pajarillo R, Barta SK, White G, Weber E, Napier E, Porter DL, Garfall AL, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: schuster sj. J Hematol Oncol. 2024 Apr 22;17(1):19. doi: 10.1186/s13045-024-01542-9. J Hematol Oncol. 2024. PMID: 38644469 Free PMC article.
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: schuster sj. J Clin Oncol. 2024 Mar 28:JCO2302329. doi: 10.1200/JCO.23.02329. Online ahead of print. J Clin Oncol. 2024. PMID: 38547425
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Chong EA, Chong ER, Therwhangher D, Nasta SD, Landsburg DJ, Barta SK, Svoboda J, Gerson JN, Ghilardi G, Paruzzo L, Fraietta JA, Weber E, Stefano N, Porter DL, Frey NV, Garfall AL, Ruella M, Schuster SJ. Chong EA, et al. Among authors: schuster sj. Transplant Cell Ther. 2024 Mar 16:S2666-6367(24)00288-4. doi: 10.1016/j.jtct.2024.03.015. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38494076
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
Akingbemi W, Kurtz G, Yegya-Raman N, Plastaras JP, Schuster SJ, Chong EA. Akingbemi W, et al. Among authors: schuster sj. Leuk Lymphoma. 2024 Mar 7:1-4. doi: 10.1080/10428194.2024.2322033. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38451075 No abstract available.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
Chong EA, Kumashie KG, Chong ER, Fabrizio J, Gupta A, Svoboda J, Barta SK, Walsh KM, Napier EB, Lundberg RK, Nasta SD, Gerson JN, Landsburg DJ, Gonzalez J, Gaano A, Weirick ME, McAllister CM, Awofolaju M, John GN, Kammerman SC, Novaceck J, Pajarillo R, Lundgreen KA, Tanenbaum N, Gouma S, Drapeau EM, Adamski S, D'Andrea K, Pattekar A, Hicks A, Korte S, Sharma H, Herring S, Williams JC, Hamilton JT, Bates P, Hensley SE, Prak ETL, Greenplate AR, Wherry EJ, Schuster SJ, Ruella M, Vella LA. Chong EA, et al. Among authors: schuster sj. J Infect Dis. 2024 Mar 4:jiae106. doi: 10.1093/infdis/jiae106. Online ahead of print. J Infect Dis. 2024. PMID: 38437622
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, Waxman AJ, Chong ER, Patel V, Pajarillo R, Kulikovskaya I, Lieberman DB, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Hexner EO, Barta SK, Porter DL, Garfall AL, Schuster SJ, June CH, Ruella M. Ghilardi G, et al. Among authors: schuster sj. Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24. Nat Med. 2024. PMID: 38266761
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Among authors: schuster sj. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. Blood. 2024. PMID: 38194692 Free article. Clinical Trial.
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
Kahl BS, Jegede OA, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, Weiss M, Fishkin PA, Fenske TS, Williams ME. Kahl BS, et al. Among authors: schuster sj. J Clin Oncol. 2024 Mar 1;42(7):774-778. doi: 10.1200/JCO.23.01912. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194625 Clinical Trial.
212 results